14.91
1.46%
+0.2291
Catalyst Pharmaceuticals Inc stock is currently priced at $14.91, with a 24-hour trading volume of 203.33K.
It has seen a +1.46% increased in the last 24 hours and a -5.43% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $14.78 pivot point. If it approaches the $14.97 resistance level, significant changes may occur.
Previous Close:
$14.68
Open:
$14.84
24h Volume:
203.33K
Market Cap:
$1.76B
Revenue:
$398.20M
Net Income/Loss:
$71.41M
P/E Ratio:
14.76
EPS:
1.01
Net Cash Flow:
$61.86M
1W Performance:
-1.55%
1M Performance:
-5.43%
6M Performance:
+10.83%
1Y Performance:
-7.02%
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Name
Catalyst Pharmaceuticals Inc
Sector
Industry
Phone
305-420-3200
Address
355 Alhambra Circle, Suite 1250, Coral Gables
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-21-23 | Initiated | Oppenheimer | Outperform |
Aug-24-22 | Downgrade | ROTH Capital | Buy → Neutral |
Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
Sep-07-18 | Resumed | Piper Jaffray | Overweight |
Oct-05-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
Apr-26-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
Sep-30-14 | Reiterated | ROTH Capital | Buy |
Sep-16-14 | Reiterated | ROTH Capital | Buy |
Sep-15-14 | Reiterated | H.C. Wainwright | Buy |
Oct-21-13 | Reiterated | Aegis Capital | Buy |
Sep-24-13 | Initiated | Maxim Group | Buy |
Sep-06-13 | Reiterated | Aegis Capital | Buy |
Apr-18-13 | Initiated | Aegis Capital | Buy |
Aug-27-12 | Upgrade | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
Oct-01-09 | Upgrade | Merriman | Sell → Neutral |
May-29-09 | Downgrade | Hapoalim | Neutral → Underperform |
May-29-09 | Downgrade | Merriman Curhan Ford | Buy → Sell |
Dec-15-08 | Initiated | Merriman Curhan Ford | Buy |
Nov-28-07 | Initiated | Rodman & Renshaw | Mkt Outperform |
Jan-31-07 | Initiated | Stifel Nicolaus | Buy |
Jan-05-07 | Initiated | First Albany | Buy |
View All
Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
GlobeNewswire Inc.
Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report?
Zacks Investment Research
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
GlobeNewswire Inc.
Decoding 7 Analyst Evaluations For Catalyst Pharmaceuticals
Benzinga
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
GlobeNewswire Inc.
Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?
Zacks Investment Research
Catalyst Pharmaceuticals Inc Stock (CPRX) Financials Data
Catalyst Pharmaceuticals Inc (CPRX) Revenue 2024
CPRX reported a revenue (TTM) of $398.20 million for the quarter ending December 31, 2023, a +85.90% rise year-over-year.
Catalyst Pharmaceuticals Inc (CPRX) Net Income 2024
CPRX net income (TTM) was $71.41 million for the quarter ending December 31, 2023, a -14.05% decrease year-over-year.
Catalyst Pharmaceuticals Inc (CPRX) Cash Flow 2024
CPRX recorded a free cash flow (TTM) of $61.86 million for the quarter ending December 31, 2023, a -46.68% decrease year-over-year.
Catalyst Pharmaceuticals Inc (CPRX) Earnings per Share 2024
CPRX earnings per share (TTM) was $0.61 for the quarter ending December 31, 2023, a -17.57% decline year-over-year.
About Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3. The company is also developing CPP-115, a gamma-aminobutyric acid aminotransferase inhibitor for the treatment of refractory infantile spasms; and CPP-109, a vigabatrin tablet. It has license agreements with Northwestern University, New York University and the Feinstein Institute for Medical Research, and BioMarin Pharmaceutical Inc. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Cap:
|
Volume (24h):